Document:

EX-10.1

 Exhibit 10.1 

CONSULTING AGREEMENT 

This Consulting Agreement (the “Agreement”) is dated as of June 4, 2012 by and between ROBERT F. ROSCIGNO PHD
CONSULTING, LLC, a North Carolina limited liability company with a principal place of business at 7415 Acquarina Beach Drive, Unit 403, Melbourne Beach, FL 32951-3934 (“LLC”), Robert Roscigno, Ph.D., an employee of LLC referred to herein
as “Consultant”, and GeNO LLC, a Delaware limited liability company with a principal place of business at 2941 Oxbow Circle, Cocoa, FL 32926 (“GeNO”) (each a “Party,” and together the
“Parties”). 
 WHEREAS, GeNO desires to retain Consultant to provide services to GeNO, and LLC and Consultant agree to
provide Consultant’s services to GeNO, all on the terms and conditions set forth herein; 
 NOW, THEREFORE, for good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, and in consideration of the mutual promises herein contained, the Parties hereto agree as follows: 

1. Engagement as Consultant. During the Term (as defined below), GeNO agrees to retain the services of Consultant as an
independent contractor to provide the services set forth on Exhibit A (the “Services”), and LLC and Consultant agree that Consultant will perform such Services, on the terms and subject to the conditions set forth herein. LLC
and Consultant agree that Consultant shall devote not less than eighty percent (80%) of Consultant’s working time to the performance of the Services. It is understood that Consultant will devote the remaining 20% of his working time on
unrelated activities for other clients. 
 2. Payment; Expenses. 

(a) Payment. The fees to be paid to LLC for Consultant’s performance of the Services shall be paid in accordance with the fee
schedule set forth on Exhibit A. 
 (b) Business Expenses. All reasonable and necessary expenses incurred by Consultant in the
performance of the Services and consistent with budgets agreed to in writing by GeNO and Consultant prior to the incurrence thereof shall be reimbursed within thirty (30) days following production of expense statements or receipts for such
expenses and such other information as GeNO may require and in accordance with the applicable policies and procedures of GeNO. 
 3.
Relationship of the Parties. With respect to the Services and the compensation to be paid to LLC therefor, LLC and Consultant on the one hand, and GeNO on the other shall be independent contractors. Consultant shall perform no act
inconsistent with such status, and shall have no authority to act for or in the name of GeNO or to bind GeNO to any obligations of any nature whatsoever. GeNO shall not be responsible for any of Consultant’s federal and state taxes, withholding
or social security with respect to amounts paid to Consultant under this Agreement. Consultant further agrees that GeNO shall not be responsible for Consultant’s insurance or other benefits. 

  
 -1- 

 4. Nondisclosure Obligation. 

(a) Nondisclosure. LLC and Consultant shall maintain in strict confidence, and shall use and disclose only as authorized by GeNO, all
Confidential Information (as defined herein) that LLC or Consultant obtains or receives in connection with the performance of the Services. Notwithstanding the foregoing, LLC and Consultant may disclose Confidential Information that is required by
law or regulation of any governmental authority or any order of any court, agency or proceeding to be disclosed, provided that LLC or Consultant immediately notifies GeNO of any such requirement and give GeNO a reasonable time to obtain an
injunction or take other action it deems appropriate to prevent such disclosure. 
 (b) Confidential Information.
“Confidential Information” shall mean any of the following information regarding GeNO or any members, customers, clients, contractors, consultants, licensees or affiliates of GeNO: any and all trade secrets or confidential business
information, including without limitation information regarding research and development activities; computer software; protocols, procedures and related written materials; show-how and know-how; business plans and strategies; pricing and costing
policies; member, customer and vendor lists; and nonpublic financial information. “Confidential Information” shall not include: (i) information that may be disclosed generally or is in the public domain through no fault of LLC
or Consultant; (ii) information received from a third party outside GeNO that was disclosed without a breach of any confidentiality obligation; and (iii) information approved for release by written authorization of GeNO. 

5. Assignment of Inventions; Grant of License. 

(a) For purposes of this Agreement, the term “Inventions” shall mean all developments, concepts, ideas, expressions,
processes, improvements, plans, drawings, designs, models, formulations, specifications, methods, techniques, innovations, creations, formulas, algorithms, data, computer databases, reports, papers, writings, photographs, other works of authorship,
and know-how and show-how (including all records pertaining to any of the foregoing), whether or not reduced to writing and whether or not patented or patentable or registered or registrable under patent, copyright, trademark or similar statute. For
purposes of this Agreement, the term “Assigned Inventions” shall mean (i) any and all Inventions that arise out of or are based upon any trade secrets or confidential business information of GeNO (regardless of whether such
Inventions were made, conceived, originated, authored, created, learned or reduced to practice by LLC or Consultant at GeNO’s facilities or during regular business hours or utilizing resources of GeNO) and (ii) any and all Inventions that
are made, conceived, originated, authored, created, learned or reduced to practice by LLC or Consultant, either alone or together with others, in connection with the performance of the Services (regardless of whether such Inventions were made,
conceived, originated, 

  
 -2- 

 
authored, created, learned or reduced to practice by LLC or Consultant at GeNO’s facilities or during regular business hours or utilizing resources of GeNO). For purposes of this Agreement,
the term “Proprietary Rights” shall mean (x) any and all rights under or in connection with any copyrights, copyright applications, trademarks, trademark applications, service marks, service mark applications, trade names,
trade name applications, mask works, trade secrets and/or other intellectual property rights with respect to Assigned Inventions and (y) the goodwill associated with any and all of the rights referred to in the foregoing clause (x). 

(b) LLC and Consultant hereby acknowledge and agree that those Assigned Inventions and Proprietary Rights that are original works of
authorship protectable by copyright are “works made for hire” for GeNO, as that term is defined in the United States Copyright Act (the “Work Product”). 

(c) If any component of the Assigned Inventions or Proprietary Rights either does not qualify as a “work made for hire” under U.S.
copyright law, or is subject to protection under patent, trademark, trade secret or other intellectual property law, LLC and Consultant hereby irrevocably and exclusively assign to GeNO all of their right, title and interest in and to any and all
such Assigned Inventions and Proprietary Rights. LLC and Consultant agree to give GeNO prompt written notice of any Assigned Invention or Proprietary Right and agrees to execute such instruments of transfer, assignment, conveyance or confirmation
and such other documents as GeNO may request to evidence, confirm or perfect the assignment of all of their right, title and interest in and to any and all Assigned Inventions and Proprietary Rights. LLC and Consultant hereby waive and quitclaim to
GeNO any and all claims of any nature whatsoever that they may now or hereafter have for infringement of any Proprietary Rights assigned hereunder to GeNO. 

6. Term; Termination. The term of this Agreement (the “Term”) shall commence on the Effective Date and continue
in full force and effect until terminated by either Party: (a) if the other Party has materially defaulted in the performance of any of its obligations under this Agreement and has not cured such default within ten (10) days of receipt of
written notice from the non-defaulting Party of such default or (b) for any reason or no reason on ten (10) days written notice to the other Party. 

7. Assignment. This Agreement and each of the promises and covenants contained herein shall be binding upon and shall inure to
the benefit of each of LLC and Consultant and GeNO their respective successors and assigns, except that the obligations of LLC and Consultant under Section 1 are personal in nature and may be only be assigned with the prior written consent of
GeNO. 
 8. Insurance. During the Term, Consultant shall carry such workers’ compensation, comprehensive general and
contractual liability and comprehensive automobile insurance as is reasonable and customary in Consultant’s industry. 

  
 -3- 

 9. Miscellaneous. Any waiver by GeNO of a breach of any provision of this Agreement
shall not operate or be construed as a waiver of any subsequent breach hereof. The obligations of LLC and Consultant under this Agreement shall survive the termination of their relationship with GeNO indefinitely, or for such shorter period as may
be specified herein for a particular obligation. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Florida without regard to conflicts of law principles. This Agreement represents the complete agreement
of the Parties with respect to the subject matter contained herein, all prior and contemporaneous agreements between the Parties with respect thereto being merged and may be amended or modified only by a writing executed by each Party hereto.
Consultant recognizes and agrees that the enforcement of this Agreement is necessary to ensure the preservation, protection and continuity of the confidential business information, trade secrets and goodwill of GeNO. 

IN WITNESS WHEREOF, the undersigned Consultant and GeNO have executed this Agreement as of the date first written above. 

 

			
	GENO, LLC
		
	By:	 	 /s/ David H. Fine

	Name:	 	David H. Fine, Ph.D.
	Title:	 	President
	
	ROBERT F. ROSCIGNO PHD CONSULTING, LLC
		
	By:	 	 /s/ Robert F. Roscigno

	Name:	 	Robert F. Roscigno
	Title:	 	President

  

	
	CONSULTANT:
	
	 /s/ Robert F. Roscigno

	 Robert F. Roscigno, Ph.D.

  
 -4-EX-10.2

 Exhibit 10.2 

SEVERANCE AGREEMENT 

THIS SEVERANCE AGREEMENT (the “Agreement”), made as of November 5, 2012 (the “Effective Date”), is
entered into by GeNO LLC, a Delaware limited liability company (the “Company”), and Kurt Dasse (the “Employee”). 

WHEREAS, the parties wish to establish in advance the terms of the Employee’s severance arrangement in the event that the Employee’s
employment with the Company is terminated under specified circumstances. 
 NOW THEREFORE, in consideration of the mutual covenants and
promises contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties to this Agreement, the parties agree as follows: 

1. Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 

1.1 “Cause” shall mean (a) a good faith finding by the Board (i) of repeated and willful failure of the Employee
after written notice to perform his reasonably assigned duties for the Company where such duties are commensurate with the Employee’s position, or (ii) that the Employee has engaged in dishonesty, gross negligence or misconduct, which
dishonesty, gross negligence or misconduct has had a substantial adverse effect on the Company; (b) the conviction of the Employee of, or the entry of a pleading of guilty by the Employee to, any a felony; or (c) a breach by the Employee
of any material provision of his Invention, Non-Disclosure, Non-Competition and Non-Solicitation Agreement (the “Obligations Agreement”), which failure, act of dishonesty, gross negligence, misconduct or breach, in the case of
clauses (a) and (c), is not cured within ten (10) days after written notice thereof or which failure, act of dishonesty, gross negligence, misconduct or breach, in the case of clauses (a) and (c), the Board determines in good faith is
not curable. 
 1.2 “Good Reason” for termination shall exist upon (a) mutual written agreement by the Employee and
the Company that Good Reason exists; or (b) without the prior written consent of the Employee, (i) a change by the Company in the location at which the Employee performs his principal duties for the Company to a location not on the East
Coast of the United States; (ii) a reduction of the Employee’s total annual compensation (other than in connection with, and substantially proportionate to, reductions by the Company of the total annual compensation of its key employees
generally); or (iii) a significant diminution in the Employee’s position, authority or responsibilities. 
 1.3
“Disability” shall mean the Employee’s absence from the full-time performance of the Employee’s duties with the Company for at least 180 days in any twelve-month period as a result of incapacity due to mental or physical
illness. 
 1.4 “Severance Period” shall mean the period of (a) eighteen (18) months immediately following the
effective date of termination of employment minus (b) the number of months that the Employee continued to be employed by the Company after the Sale Date. 

  
 1 

 1.5 “Sale” shall mean (a) the sale of the Company by merger in which the
members of the Company in their capacity as such no longer own a majority of the outstanding equity interests of the Company (or its successor); (b) any sale of all or substantially all of the assets of the Company (other than in a spin-off or
similar transaction); (c) any sale in one transaction or a series of related transactions of more than fifty percent (50%) of the outstanding equity interests of the Company (other than a transaction in which all or substantially all of
the individuals and entities who were beneficial owners of the equity interests immediately prior to such transaction beneficially own, directly or indirectly, more than fifty percent (50%) of the outstanding equity interests of the resulting,
surviving or acquiring corporation in such transaction); or (d) any other acquisition of the business of the Company, as determined by the Board of Directors. 

1.6 “Sale Date” shall mean the first date on which a Sale occurs. 

2. Benefits to Employee. 

2.1 Payments Upon Termination. In the event the Employee’s employment with the Company is terminated on or after the Sale Date by
the Employee for Good Reason or by the Company (other than for Cause, Disability or death), then during the Severance Period the Company shall (a) continue to pay to the Employee his then-current monthly base salary preceding the date of
termination (the “Severance Payment”) and (b) continue to provide to the Employee the health and disability benefits provided to him (to the extent such benefits can be provided to non-employees, or to the extent such benefits
cannot be provided to non-employees, then the cash equivalent thereof). Notwithstanding the foregoing, if the Employee becomes re-employed with another employer, or if the Employee receives cash compensation as an independent consultant, then
(x) the Company shall deduct from the monthly base salary payment the amount paid to the Employee as cash compensation by the new employer or otherwise received by the Employee as an independent consultant and (y) if the Employee is
eligible to receive substantially equivalent health insurance benefits from the new employer on terms at least as favorable to the Employee and his family as those being provided by the Company, the Company shall no longer be required to provide
those particular benefits to the Employee and his family. 
 2.2 Release. The obligation of the Company to make the payments and
provide the benefits to the Employee under Section 2.1 shall (a) be conditioned upon (i) the execution by the Employee of a release of claims in a form reasonably acceptable to the Company and the Employee and (ii) the
Employee’s compliance with the material provisions of the Obligations Agreement, and (b) constitute the sole remedy of the Employee in the event of a termination of the Employee’s employment in the circumstances set forth in
Section 2.1. 
 3. Not an Employment Contract. The Employee acknowledges that this Agreement does not constitute a contract of
employment or impose on the Company any obligation to retain the Employee as an employee and that this Agreement does not prevent the Company or the Employee from terminating his employment at any time. 

  
 2 

 4. Miscellaneous. 

4.1 Notices. Any notices delivered under this Agreement shall be deemed duly delivered four business days after it is sent by
registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent for next-business day delivery via a reputable nationwide overnight courier service, in each case to the address to the Company, at 2941
Oxbow Circle, Cocoa, Florida 32926; and to the Employee at the Employee’s address indicated on the signature page hereto (or to such other address as either the Company or the Employee may have furnished to the other in writing in accordance
herewith). 
 4.2 Entire Agreement; Waivers. This Agreement constitutes the entire agreement between the parties and supersedes all
prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Employee. No delay or
omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be
construed as a bar or waiver of any right on any other occasion. 
 4.3 Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of Florida (without reference to the conflicts of laws provisions thereof). 
 4.4
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may
succeed to the Company’s assets or business. 
 4.5 Severability. In case any provision of this Agreement shall be invalid,
illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

4.6 Withholding. All payments provided for under this Agreement shall be subject to applicable withholding taxes. 

4.7 Employee’s Acknowledgements. The Employee acknowledges that he: (a) has read this Agreement; (b) has been
represented in the preparation, negotiation, and execution of this Agreement by legal counsel of the Employee’s own choice or has voluntarily declined to seek such counsel; and (c) understands the terms and consequences of this Agreement.

 [the next page is the signature page] 

  
 3 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set
forth above. 
  

			
	GENO LLC
		
	By:	 	 /s/ David Fine

	Name:	 	David Fine
	Title:	 	Chairman
	
	EMPLOYEE:
	
	/s/ Kurt A. Dasse
	Name:	 	Kurt A. Dasse

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]